

APPENDIX B
MARKED-UP VERSION OF AMENDED CLAIMS

1. (Amended) A method of [inhibiting a degenerative condition of a retinal photoreceptor cell] treating a retinal disease or condition, which disease or condition is caused by damage, disruption, or degeneration of an RPE cell or a Muller cell, said method comprising contacting [a photoreceptor cell] an RPE cell or Muller cell having [a degenerative] said disease or condition with a composition comprising a brimonidine compound in an amount effective to inhibit the [degenerative condition] disease or condition.

5. (Amended) A method of treating a degenerative condition of retinal photoreceptors caused by damage, disruption, or degeneration of an RPE cell or a Muller cell, said method comprising administering to a subject in need thereof, a composition comprising a brimonidine compound in an amount effective to delay or reverse said condition.

13. (Twice amended) The method of claim 1 or 5, wherein said condition is retinitis pigmentosa caused by mutations in genes expressed in RPE cells.

14. (Amended) A method of reversing or delaying degeneration of a [photoreceptor cell] Muller cell in a retina, comprising contacting said retina with a composition that includes an amount of a brimonidine compound effective to inhibit GFAP expression in Müller cells.

15. (Amended) A method of reversing or delaying degeneration of a Muller cell in a retina, comprising contacting said retina with a composition that includes an amount of a

brimonidine compound effective to stimulate upregulation of glutamine synthetase in Müller cells.